 |
 |
gm1 ganglioside is a normal part of nerve cell membranes. It is currentlt being studied by the Hahnemann/MCP group in Philadelphia. Their findings were published in the June issue of Neurology[J,S. Schneider et al, GM1 ganglioside treatment of Parkinson's disease].This reported the effects on ten PD patients and these effects were highly salutory. The Hahnman-MCP group is noworganizing a controlled study of GM1 in a larger group of PD patients. This will be a double blind placebo controlled study. They are now looking for volunteers for this study. They seem to be looking for patients who have relatively mild to moderate symptoms and who are currently experiencing a good,reliable response to traditional anti-Parkinsonian therapies such as sinemet. You can get further information about this study from Jillian Chapas-Crilly at 215-762-3066.Abakalk(Sam Kalkstein)